Artificial Intelligence in Diabetes Management Market Report 2026

The artificial intelligence in diabetes management market size has grown exponentially in recent years. It will grow from $0.8 billion in 2025 to $1.06 billion in 2026 at a compound annual growth rate (CAGR) of 33.2%. The growth in the historic period can be attributed to rising global diabetes prevalence, early adoption of glucose monitoring devices, growth of digital health applications, increased patient self management awareness, expansion of wearable health technologies.

The artificial intelligence in diabetes management market size is expected to see exponential growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 33.7%. The growth in the forecast period can be attributed to demand for personalized treatment plans, AI driven decision support adoption, integration of connected medical devices, growth of home based care models, focus on preventive diabetes management. Major trends in the forecast period include AI powered glucose monitoring systems, growth of personalized diabetes care, integration of smart insulin delivery, expansion of predictive glycemic analytics, adoption of remote diabetes management.

The increasing prevalence of diabetes is expected to drive the growth of artificial intelligence in the diabetes management market in the future. Diabetes occurs when blood glucose, or blood sugar, is elevated, leading to complications such as eye issues, heart attacks, strokes, kidney problems, and more. Artificial intelligence aids in diabetes management by providing insights into high or low blood sugar levels in diabetic patients and collecting previously unused data. For example, in June 2024, according to National Health Service (NHS England), a UK-based publicly funded healthcare system, 3,615,330 people registered with a GP were diagnosed with non-diabetic hyperglycaemia - also known as pre-diabetes - in 2023, compared to 3,065,825 in 2022, reflecting an 18% increase. As a result, the growing prevalence of diabetes is fueling the expansion of artificial intelligence in the diabetes management market.

Major companies operating in the artificial intelligence in diabetes management market are introducing new products, such as wearable devices for glucose monitoring, to strengthen their competitive position. A wearable glucose monitoring device is a small and technologically advanced device developed to continuously or periodically measure and track an individual’s blood glucose levels. For instance, in October 2023, Dexcom Inc., a US-based medical device manufacturer, launched its next-generation G7 continuous glucose monitoring (CGM) system. This system is designed for use by all individuals with diabetes across the nation, including pregnant patients and those aged two years and above. By providing alerts for severe hypoglycemia up to 20 minutes in advance, the Dexcom CGM device helps reduce uncertainty in diabetes management. The system also features a 12-hour grace period for easier sensor replacement and remote monitoring that enables glucose data sharing with up to 10 followers.

In July 2024, GE HealthCare, a US-based provider of medical imaging and artificial intelligence solutions, acquired the clinical artificial intelligence business of Intelligent Ultrasound for an undisclosed amount. Through this acquisition, GE HealthCare plans to enhance its AI-driven diagnostic platforms by combining Intelligent Ultrasound’s real-time image analysis software with its global imaging network and enterprise services. Intelligent Ultrasound Group plc is a UK-based company that develops AI-powered ultrasound tools delivering real-time image analysis to improve diagnostic precision.

Major companies operating in the artificial intelligence in diabetes management market are Alphabet; F. Hoffmann-La Roche; Abbott Laboratories; Medtronic; Dexcom; Insulet; Tandem Diabetes Care; LifePlus; Livongo Health; Xeris Pharmaceuticals; Virta Health; Informed Data Systems; Bigfoot Biomedical; Lark Technologies; Smart Meter; Diabeloop; Quin Technology; Wellthy Therapeutics; Admetsys; DreaMed Diabetes; Eyenuk; Glooko; PKvitality; Glytec; Hygieia; TypeZero Technologies; Nemaura Medical; GlucoMe; PredictBGL; Voluntis.

North America was the largest region in the artificial intelligence (AI) in diabetes management market in 2025. The regions covered in the artificial intelligence in diabetes management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence in diabetes management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the AI in diabetes management market by increasing costs for imported glucose monitors, insulin delivery devices, sensors, and wearable components. These impacts are most evident in device heavy segments and home care settings across north america and asia pacific. Higher equipment costs have influenced affordability and adoption rates. At the same time, tariffs are encouraging localized device manufacturing, regional innovation, and software driven diabetes management solutions.

The artificial intelligence in diabetes management market research report is one of a series of new reports that provides artificial intelligence in diabetes management market statistics, including artificial intelligence in diabetes management industry global market size, regional shares, competitors with a artificial intelligence in diabetes management market share, detailed artificial intelligence in diabetes management market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence in diabetes management industry. This artificial intelligence in diabetes management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence in diabetes management involves the use of AI technologies and algorithms to analyze patterns in behavior that may lead to fluctuations in blood sugar levels, whether it be hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar), in patients with diabetes. The application of artificial intelligence in diabetes management contributes to improvements in various aspects of diabetes care, including decision support, prediction of blood sugar levels, lifestyle guidance, and treatment management.

The primary devices integrated into artificial intelligence in diabetes management include diagnostic devices, glucose monitoring devices, insulin delivery devices, and others. Diagnostic devices play a crucial role in determining the nature or underlying cause of specific phenomena, particularly those associated with health issues such as diabetes. The various techniques employed in this context include case-based reasoning and intelligent data analysis. These technologies find application in diverse settings, including hospitals, clinics, home care settings, and research institutes.

The artificial intelligence in diabetes management market consists of revenues earned by entities by providing automated retinal screening, clinical decision support, disease prediction, and treatment management. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence in the diabetes management market also includes sales of glucose monitors, support vector machines, and smart wearables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.